Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD22+ Relapsed/Refractory B-ALL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 0 results

Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Early research (Phase 1)UnknownNCT00004086
What this trial is testing

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

Who this might be right for
LeukemiaLymphoma
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Early research (Phase 1)UnknownNCT04204161
What this trial is testing

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Who this might be right for
Relapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, Childhood
Shenzhen BinDeBio Ltd. 30
Early research (Phase 1)Study completedNCT00450944
What this trial is testing

Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Leukemia
Albert Einstein College of Medicine 10
Not applicableUnknownNCT04546906
What this trial is testing

Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 20
Early research (Phase 1)Ended earlyNCT01408160
What this trial is testing

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Adult B Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia
Albert Einstein College of Medicine 18
Testing effectiveness (Phase 2)Study completedNCT03289455
What this trial is testing

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
B Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic Leukemia+1 more
Autolus Limited 23
Early research (Phase 1)UnknownNCT03999697
What this trial is testing

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Who this might be right for
Diffuse Large B Cell LymphomaFollicular LymphomaPrimary Cutaneous Follicle Centre Lymphoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT03739814
What this trial is testing

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) 84
Testing effectiveness (Phase 2)Study completedNCT04340167
What this trial is testing

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia
Beijing Boren Hospital 14
Testing effectiveness (Phase 2)UnknownNCT01354457
What this trial is testing

Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+

Who this might be right for
Acute Lymphoblastic Leukemia
Nantes University Hospital 21
Early research (Phase 1)UnknownNCT05223686
What this trial is testing

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Who this might be right for
Acute Lymphoblastic Leukemia
Hrain Biotechnology Co., Ltd. 18
Early research (Phase 1)Study completedNCT01925131
What this trial is testing

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Who this might be right for
Acute Leukemias of Ambiguous LineageB-cell Adult Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia+2 more
SWOG Cancer Research Network 50